NERVGEN PHARMA CORP.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Emerging growth company
State of Incorporation British Columbia, Canada
Business Address SUITE 1703 - 595 BURRARD STREET, VANCOUVER, A1, V7X 1J1
Mailing Address SUITE 1703 - 595 BURRARD STREET, VANCOUVER, A1, V7X 1J1
Phone 6047225361
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 40-F Canadian company annual report | March 31, 2026 | View on SEC |
| 6-K Foreign company current report | March 13, 2026 | View on SEC |
| 6-K Foreign company current report | February 13, 2026 | View on SEC |
| 6-K Foreign company current report | February 10, 2026 | View on SEC |
| 6-K Foreign company current report | January 8, 2026 | View on SEC |
Annual Reports
40-F March 31, 2026
- Advancing lead drug candidate NVG-291 for nerve repair in spinal cord injuries.
- Successfully raised $23 million CAD in 2023 to fund ongoing clinical research.
Related Companies
Companies in the same industry (SIC: 2834)
Connect Biopharma Holdings Ltd
CNTB Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN Pharmaceutical Preparations
BIOHARVEST SCIENCES INC.
BHST Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.